11/12
12:22 pm
KROS
Keros Therapeutics (NASDAQ:KROS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $27.00 price target on the stock, up previously from $23.00.
Low
Report
Keros Therapeutics (NASDAQ:KROS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $27.00 price target on the stock, up previously from $23.00.
11/12
11:28 am
KROS
Rating for KROS
Low
Report
Rating for KROS
11/12
11:28 am
KROS
Rating for KROS
Low
Report
Rating for KROS
11/11
09:31 am
KROS
Rating for KROS
Low
Report
Rating for KROS
11/11
09:31 am
KROS
Rating for KROS
Low
Report
Rating for KROS
11/6
08:33 am
KROS
Rating for KROS
Medium
Report
Rating for KROS
11/6
08:33 am
KROS
Rating for KROS
Medium
Report
Rating for KROS